

A prospective, non-interventional, multi-country cohort study of the effectiveness and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis (GALOCEAN)

First published: 11/04/2023

Last updated: 23/04/2024

Study

Ongoing

Administrative details

PURI

<https://redirect.ema.europa.eu/resource/105477>

EU PAS number

EUPAS50214

Study ID

105477

DARWIN EU® study

No

Study countries

Austria

Belgium

France

Germany

Ireland

Italy

Netherlands

Norway

United Kingdom

Study description

To describe the effectiveness, treatment patterns, quality of life, and safety of patients with moderately or severely active ulcerative colitis treated with filgotinib in a real-world setting

Study status

Ongoing

Research institution and networks

Institutions

Galapagos

First published: 01/02/2024

Last updated
01/02/2024

Institution

Contact details

Study institution contact

Galapagos NV Medical Information

Study contact

medicalinfo@glpg.com

Primary lead investigator

Galapagos NV Study Director

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

31/05/2022

Study start date

Actual:

12/06/2023

Date of final study report

Planned:

30/06/2026

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Galapagos NV

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

Main study objective:

To describe the real-world clinical treatment persistence in adult patients with moderately or severely active UC treated with filgotinib for approximately 52 weeks in routine clinical practice.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

FILGOTINIB MALEATE

Medical condition to be studied

Colitis ulcerative

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

600

Study design details

Outcomes

Treatment persistence rate at week 52, Treatment persistence rate at weeks 10 and 24, Clinical response rate, Clinical remission rate, change from baseline in Health-Related Quality of Life (HRQoL) as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), Urgency Numeric Rating Scale (NRS), and Functional Assessment of Chronic Illness Therapy-Fatigue score (FACIT-F), rate of AE and SAE during 52 weeks

Data analysis plan

In general, data analysis will be descriptive and use summary statistics. Continuous variables will include the number of patients (N), mean, standard deviation (SD), median, interquartile range (IQR), minimum, and maximum, together with the number of missing values. Categorical variables will include numbers and percentages, with missing values as separate category. Descriptive summary statistics will be conducted for all effectiveness measurements, as well as baseline characteristics, demographics, medical and treatment histories, HRU, AEs, and HRQoL. More advanced analysis (e.g. time-to-event, change from baseline) may also be conducted.

Data management

Data sources

Data sources (types)

Other

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No